Recent advances in the treatment of refractory gastrointestinal angiodysplasia.

Autor: Becq A; Gastroenterology Department, Paris-Est Créteil University, Henri Mondor Hospital, AP HP, Créteil, France., Sidhu R; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.; Academic Unit of Gastroenterology and Hepatology, Sheffield Teaching Hospitals, NHS Foundation Trust, Sheffield, UK., Goltstein LCMJ; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., Dray X; Sorbonne University, Center for Digestive Endoscopy, Saint Antoine Hospital, AP HP, Paris, France.
Jazyk: angličtina
Zdroj: United European gastroenterology journal [United European Gastroenterol J] 2024 Oct; Vol. 12 (8), pp. 1128-1135. Date of Electronic Publication: 2024 Sep 04.
DOI: 10.1002/ueg2.12648
Abstrakt: Gastrointestinal angiodysplasia (GIA) is a common, acquired, vascular abnormality of the digestive tract, and a frequent cause of bleeding. Refractory GIA criteria usually include recurrent bleeding, transfusions and/or repeat endoscopy. Pharmacological and interventional treatments have been the subject of recent high-quality publications. This review provides an overview of the latest updates on non-endoscopic management of refractory GIA. Aortic valve replacement has shown its efficacy in Heyde syndrome and should be considered if indicated. Anti-angiogenic drugs, such as Octreotide and Thalidomide, are efficient treatments of refractory GIA-related bleeding. Somatostatin analogs should, based on efficacy and tolerance profile, be considered first. In the future, a better understanding of the physiopathology of GIA might help develop new-targeted therapies.
(© 2024 The Author(s). United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
Databáze: MEDLINE
Externí odkaz: